Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

Our working hypothesis postulates that lipolysis is a determinant of inflammation in adipose tissue (AT). Inhibition of lipolysis, e.g. using the oldest normolipidemic drug, nicotinic acid, has proved valuable to combat the metabolic syndrome. Our proposal will determine whether part of the beneficial effects of this antilipolytic compound is due to a diminution of AT inflammation.

To this aim, the effect of nicotinic acid or placebo will be studied in male obese subjects with or without a training program which goal is to enhance lipolysis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Treatments: Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• Signature of informed consent form

• Age 25 to 45 year-old

• Male, insulin resistant obese subjects (30- Blood arterial pressure<140/90 mmHg

Exclusion Criteria:

• History of cardiovascular disease

• Treatment with drugs which can interfere with cardiovascular system and autonomic nervous system (i.e. beta blockers).

• Treatment with nicotinic acid

• Treatment with fibrates, statins, cholestyramine and ezetimibe

• Treatment with thiazidics

• Fasted hyperglycaemia > 1,26 g/l (Diabetes)

• Triglycerides >5 g/l

• Blood arterial pressure > 140/90 mm Hg